Evaluation of early hospital discharge after allogeneic bone marrow transplantation for chronic myeloid leukemia

Sao Paulo Medical Journal

Volumn 125, Issue 3, 2007, Pages 174-179

  Nicolau, José Eduardo ^a,b   de Melo, Leila Maria Magalhões Pessoa ^a   Sturaro, Daniel ^a   Saboya, Rosaura ^a   Dulley, Frederico Luiz ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Santa Casa de Misericórdia de São Paulo   (Brazil)

Author keywords

Ambulatory care; Bone marrow transplantation; Chronic myeloid leukemia; Length of stay; Retrospective studies

Indexed keywords

ACICLOVIR; BUSULFAN; CEFEPIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; MELPHALAN; METHOTREXATE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; BRAZIL; CATHETER INFECTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEATH; FEMALE; GRAFT INFECTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OUTPATIENT CARE; PNEUMONIA; PSEUDOMONAS; SEPSIS; URINARY TRACT INFECTION; WHOLE BODY RADIATION;

EID: 35348937777     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802007000300009     Document Type: Article

References (24)

1. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;98(7):2039-42.
2. O'Dwyer ME. Chronic myelogenous leukemia. Curr Opin Oncol. 2003;15(1):10-5
3. Maziarz RT, Mauro MJ. Transplantation for chronic myelogenous leukemia: yet, no, maybe so... An Oregon perspective. Bone Marrow Transplant. 2003;32(5):459-69.
4. Peters WP, Ross M, Vredenburgh JJ, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol. 1994;21(4 Suppl 7):25-31.
5. Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20(6):445-50.
6. Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant. 1999;24(6):679-84.
7. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol. 2003;25(3):179-84.
8. Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem tell transplantation. Bone Marrow Transplant. 1998;21(9):927-32.
9. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol. 1999;17(9):2811-8.
10. Westermann AM, Holtkamp MM, Linthorst GA, et al. Ar home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol. 1999;10(5):511-7.
11. Gonzalez-Ryan L, Haut PR, Coyne K, et al. Developing a pediatric outpatient transplantation program. The Children's Memorial Hospital experience. Front Biosci. 2001;6:G1-5.
12. Frey P, Stinson T, Siston A, et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant. 2002:30(11):741-8.
13. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology (Williston Park). 2000;14(2):171-85; discussion 185-6, 191-2.
14. Russell JA, Chaudhry A, Booth K, et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant. 2000;6(2):109-14.
15. Ruiz-Arguelles GJ, Gomez-Almaguer D, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OG, Jaime-Perez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol. 2001;66(4):241-4.
16. Svahn BM, Bjurman B, Myrback KE, Aschan J, Ringden O. Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant. 2000;26(10):1057-60.
17. Svahn BM, Remberger M, Myrback KE, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advatageous compared with hospital care. Blood. 2002;100(13):4317-24.
18. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-92.
19. Lawrence CC, Gilbert CJ, Peters WP. Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann Pharmacother. 1996;30(9):941-5.
20. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant. 2000;26(4):389-95.
21. Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(6):511-6.
22. Herrmann RP, Trent M, Cooney J, Cannell PK. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 1999;24(11):1213-7.
23. Egerer G, Goldschmidt H, Salwender H, et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15(2):119-23.
24. Seropian S, Nadkarni R, Jillella AP, et al. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant. 1999;23(6):599-605.